Allied Market Research


Central Nervous System (cns) Therapeutics Market

Central Nervous System (CNS) Therapeutics Market Size, Share, Competitive Landscape and Trend Analysis Report, by Disease type and, by Application : Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals

Select an option
Author's: | Roshan Deshmukh
Publish Date:

Get Sample to Email

The central nervous system (CNS) is a vital part of the nervous system that consists the brain and the spinal cord. It integrates the received information, thereafter coordinating and controlling the activities of all parts of the body. However, CNS disorders such as neurodegenerative diseases, autoimmune & inflammatory diseases, genetic disorders, cancers, and others affect the structure and function of the brain or spinal cord. Thus, CNS therapeutics are used to treat these disorders. 

The growth of the CNS therapeutics market is primarily driven by advancements in diagnostics, therapeutics, and drug discovery techniques. Moreover, increase in demand for effective CNS therapeutic options encourages major pharmaceutical companies to invest in R&D, thus creating future growth opportunities. Furthermore, rise in awareness regarding psychiatric disorders, surge in prevalence of mental illness & lifestyle-associated CNS disorders, and increase in geriatric population boost the growth of the global market. The rate of serious psychological distress among adolescents and young adults has been on a rise since past few years, which further fuels the demand for CNS therapeutics across the globe. However, stringent & protracted drug approval procedures and soaring prices of advanced treatments are projected to restrain the growth of the CNS therapeutics market. On the contrary, lucrative opportunities in emerging economies due to various factors such as rise in awareness regarding CNS disorders and increase in healthcare expenditure by government & non-government organizations are expected to provide immense opportunities for the manufacturers in the industry. 

The World Health Organization and the American Association of Neurological Surgeons conduct various seminars to increase awareness about psychological disorders and their treatments. In addition, these organizations have helped to create groups in which patients can interact with each other as well as with the professionals and can have a holistic approach toward healing, which drives the market growth. Furthermore, advancements in technologies to develop superior drug delivery system and rise in R&D activities for introduction of novel drugs are anticipated to propel the market for CNS therapeutics. Moreover, upcoming pipeline therapeutics for CNS disorders by Healthcare giants such as Biogen, Inc. and Pfizer, Inc. is projected to accelerate the growth of the market. In addition, various other key players in the global CNS therapeutics market are heavily investing to bring superior therapeutics in the market, which provides remunerative opportunities for market expansion.

The global central nervous system therapeutics market is segmented into disease type, applications, and region. Based on disease type, the market is fragmented into infectious diseases, neurodegenerative diseases, autoimmune & inflammatory diseases, genetic disorders, cancers, trauma, and psychiatric disorders. The applications covered in the study include hospital, clinic, homecare, and others. Region wise, the market is thoroughly analyzed across North America, Europe, Asia-Pacific, and LAMEA. 

This report provides a comprehensive analysis and profiles of major players such as Pfizer, Inc., Biogen, Inc., Johnson & Johnson Services, Inc., Eli Lilly and Company, Inc., Merck & Co., Inc., AstraZeneca, Novartis AG, Teva Pharmaceutical Industries Ltd., Shire Plc, and Allergan Plc. The other players in the value chain include Cipla Limited, GlaxoSmithKline plc, Lupin Limited, Otsuka Pharmaceutical Co., Ltd., Lundbeck, and others.


  • An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate region-specific plans.
  • A comprehensive analysis of the factors that drive and restrain the growth of the market is provided.
  • Region-wise and country-wise market conditions are comprehensively analyzed in this report.
  • The projections in this report are made by analyzing the current market trends and future market potential in terms of value.
  • An extensive analysis of various regions provides insights that are expected to allow companies to strategically plan their business moves.
  • Key market players within the CNS therapeutics market are profiled in this report, and their strategies are analyzed thoroughly, which help to understand the competitive outlook of global market.

Central Nervous System (CNS) Therapeutics Market Report Highlights

Aspects Details
By Disease type
  • Neurodegenerative Diseases
  • Infectious Diseases
  • Autoimmune and Inflammatory Diseases
  • Genetic Disorders
  • Cancers
  • Trauma
  • Psychiatric Disorders
  • Anxiety Disorders
  • Substance Abuse Disorders
  • Mood Disorders
  • Others
By Application
  • Hospitals
  • Clinics
  • Homecare
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players

Biogen Inc., Pfizer, Shire Plc, Eli Lilly and Company Inc., Merck & Co. Inc., Novartis AG, AstraZeneca, Johnson & Johnson Services Inc., Teva Pharmaceutical Industries Ltd., Allergan Plc

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Central Nervous System (CNS) Therapeutics Market

Global Opportunity Analysis and Industry Forecast, 2023-2032